酸化ストレスを標的とした分子状水素による心血管障害への新たなアプローチ：レビュー
Cardiovascular disease remains a leading cause of death and disability globally, with redox imbalance and inflammatory dysregulation as central pathological drivers. This review examines preclinical and clinical evidence for molecular hydrogen across a range of cardiovascular conditions, including radiation-induced cardiac injury, ischemia-reperfusion damage, myocardial and cerebral infarction, cardiac preservation, and heart transplantation. Hydrogen is delivered via inhalation, oral hydrogen-rich water, or hydrogen-rich saline injection. Its biological actions include suppression of pro-inflammatory cytokines, attenuation of excess reactive oxygen species, and activation of the Nrf2 antioxidant transcription factor, collectively modulating signal transduction and gene expression. Anti-oxidant, anti-inflammatory, and anti-apoptotic properties have been documented, though precise mechanistic pathways remain incompletely characterized. No clinical toxicity has been reported, and a mild hormetic-like response may partly account for observed benefits. The cumulative evidence suggests potential utility of hydrogen in ROS- and inflammation-driven cardiac pathology.
Molecular hydrogen suppresses pro-inflammatory cytokine production and excess reactive oxygen species while activating the Nrf2 antioxidant transcription factor, thereby modulating downstream signal transduction and gene expression to exert anti-inflammatory and anti-apoptotic effects.
This study combines multiple delivery routes. As a general principle, the most efficient route for routine hydrogen intake is inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/31159153